Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Teams Up with US Merck’s Subsidiary for Clinical Research of DS-8201/Keytruda Combo
September 25, 2018
- Astellas to Create New Business beyond Core Prescription Drug Business, Aims to Launch Several Products by FY2020
September 21, 2018
- Meiji Seika Pharma Commences Shipment of KM Biologics’ Flu Vaccine
September 21, 2018
- Roxadustat Hit Goal in CKD Patients with Anemia Not on Dialysis in Multinational PIII Study: Astellas
September 21, 2018
- Meiji Files Aricept Generic for Lewy Body Dementia to Win Full Indications
September 21, 2018
- Growing Number of Drug Makers Introducing LGBT-Friendly Policies
September 20, 2018
- Sosei, Allergan Suspend Joint Clinical Development of AD Therapy due to Unexpected Toxicology Findings
September 20, 2018
- Otsuka Pharmaceutical Factory Accuses AY Pharmaceuticals, Yoshindo for Patent Infringement on Transfusion Product
September 20, 2018
- Ono, US Bioventure Fate Therapeutics Hook Up for CAR-T Therapies
September 19, 2018
- Nichi-Iko to Copromote 5 Elmed Eisai Products from October
September 18, 2018
- Astellas Joins Hands with Gene Therapy Biotech for ALS Treatment Program
September 18, 2018
- Takeda Gets China OK for Shire Takeover
September 18, 2018
- Sekisui Chemical Hooks Up with Regenerative Medicine Upstart
September 14, 2018
- Shionogi Grabs Rights to Rohto’s Cell-Based Hepatic Cirrhosis Therapy
September 14, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- Ex-AZ Exec Nogami Tapped to Lead Takeda Consumer Healthcare
September 13, 2018
- Kowa Continues Heavy GP Pitch for Parmodia in July: Anterio
September 13, 2018
- Nippon Shinyaku Eyes Conditional Early OK for Sakigake DMD Drug, Daiichi Sankyo Redoing PI/II for Its Antisense
September 12, 2018
- Quizartinib Earns Japan Orphan Status for AML: Daiichi Sankyo
September 12, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…